US Stocks · Information Technology · Technology Hardware & Storage
Q4 FY25 is the full year minus the first nine months; the other quarters come from their 10-Q filings.
Ainos, Inc. develops AI Nose (an AI-powered digital olfaction/e-nose platform that converts scent signals into “Smell ID”) and VELDONA® (a low-dose oral interferon platform spanning human therapeutics and animal health products), with commercialization that includes subscription-based deployments for AI Nose and product sales/distribution for certain VELDONA offerings.
Ainos is an early-stage SmellTech company positioning AI Nose for scalable deployments in environments such as semiconductor manufacturing and care/healthcare settings, differentiating via a device-plus-software approach and a recurring SmellTech-as-a-Service model.
Key operating focuses include (1) AI Nose / scent digitization commercialization and (2) VELDONA® therapeutics & animal health development and sales/distribution.
GET /api/financials/key-metrics?symbol=AIMD| USD | FY2025 |
|---|---|
| Revenue | $124.2K |
| Gross margin | 82.89% |
| Operating margin | -11268.32% |
| Net income | -$14.8M |
| EPS (basic) | -3.46 |
| Free cash flow | -$4.6M |
| ROIC | -66.99% |
| Net debt / EBITDA | -1.14x |
Computed from AIMD's annual 10-K filings. Margins and ROIC in percent, values in US dollars.
Headlines from public news sources, newest first. Not part of the SEC data.